Utilizing Machine Learning to Determine Risk Factors for Hospital-Acquired Infections in Cancer Patients Experiencing Pneumonia Related to Immune Checkpoint Inhibitors - Top-Institutions - MDSpire

Utilizing Machine Learning to Determine Risk Factors for Hospital-Acquired Infections in Cancer Patients Experiencing Pneumonia Related to Immune Checkpoint Inhibitors

  • By

  • Jianzhong Xie

  • Zhuo Zhao

  • Cuiyun Zhou

  • Junxiang Wang

  • Xiufang Lin

  • Lingyu Lai

  • Jinchan Yao

  • Haiyan Lin

  • Zuquan Weng

  • January 29, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Biomedical Informatics

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Computational Biology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Health Informatics

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Oncology
    • Biomedical Engineering

  • #5

    Stanford University Medical Center
    Stanford University Medical Center

    Stanford, CA

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Artificial Intelligence

Original Source(s)

Utilizing Machine Learning to Determine Risk Factors for Hospital-Acquired Infections in Cancer Patients Experiencing Pneumonia Related to Immune Checkpoint Inhibitors

  • by Jianzhong Xie, Zhuo Zhao, Cuiyun Zhou, Junxiang Wang, Xiufang Lin, Lingyu Lai, Jinchan Yao, Haiyan Lin, Zuquan Weng

  • January 29, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma